Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
October 30, 2019 16:05 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Announces Executive Departures
October 25, 2019 18:11 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
September 13, 2019 06:15 ET
|
Atara Biotherapeutics, Inc.
Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple...
Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
September 09, 2019 08:00 ET
|
Atara Biotherapeutics, Inc.
ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, which we believe play a fundamental role in the pathogenesis of multiple sclerosis Conference call and webcast to discuss results Friday,...
Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference
August 28, 2019 16:05 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
August 08, 2019 07:30 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019
August 01, 2019 16:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
July 18, 2019 23:52 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments...
Atara Biotherapeutics Announces Proposed Offering of Common Stock
July 18, 2019 16:01 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments...
Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year
July 16, 2019 07:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...